Linkedin Facebook Twitter Youtube

22 Jul bit.bio

Posted at 16:56h in by

Kathryn Corzo, President and Chief Operating Officer

Oct. 8 | 2:00pm | FLW Ballroom G 

Cambridge, MA

(Private)

bit.bio is a synthetic biology company focused on human cells, advancing medicine and enabling curative treatments. The company does this by industrializing the manufacture of human cells and making them more accessible. bit.bio’s opti-ox™ deterministic cell programming technology enables conversion of induced pluripotent stem cells into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency. The company has a cell therapy pipeline, based on txCells, focused on serious diseases that lack effective treatments. The ioCells research cell product portfolio is opening up new possibilities in research and drug discovery.

www.bit.bio



About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 110+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 6-8, 2025
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions